Investor Relations

OUR LEAD ONCOLOGY CANDIDATE, OFRA-VEC, IS CURRENTLY BEING EVALUATED IN OUR OVAL PHASE 3 REGISTRATION-ENABLING CLINICAL TRIAL IN OVARIAN CANCER. READOUT OF OVAL PFS CO-PRIMARY ENDPOINT IS EXPECTED IN THE SECOND HALF OF 2022. FOR ADDITIONAL INFORMATION AND CATALYSTS, SEE OUR CORPORATE PRESENTATION.

Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart